Sling Therapeutics is developing Linsitinib, an oral therapy for thyroid eye disease (TED) that aims to reduce the treatment burden for patients and healthcare providers. This targeted approach addresses the significant challenges associated with managing TED, improving patient outcomes and quality of life.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Thyroid eye disease (TED) presents a significant treatment burden for patients, caregivers, and physicians, often requiring frequent and invasive interventions. Current therapies may not be easily accessible or convenient for all patients, impacting their quality of life.
Solution
Sling Therapeutics is developing linsitinib, an oral small molecule therapy, to address the unmet needs in thyroid eye disease (TED) treatment. Linsitinib inhibits the IGF-1R target, a validated mechanism in TED, offering a convenient and less burdensome treatment option. The therapy aims to improve patient outcomes by providing an easily administered oral medication that can potentially reduce the need for more invasive procedures. Linsitinib has an established safety profile based on data from over 800 patients. The company is currently conducting a Phase 2b trial to further evaluate the efficacy and safety of linsitinib in TED patients and is also exploring its potential in other autoimmune and rare diseases.
Target Audience
The primary target audience includes patients with thyroid eye disease, as well as ophthalmologists, endocrinologists, and physicians specializing in rare diseases.
Features
- Oral small molecule formulation for convenient administration
- IGF-1R inhibition, a validated target in thyroid eye disease
- Established safety profile based on data from over 800 patients
- Currently in Phase 2b clinical trials for thyroid eye disease
- Potential application for additional autoimmune and rare diseases